BTSGHealthcare · Health Information ServicesThe 18 Wall Street analysts covering BrightSpring Health Services, Inc. hold a median 12-month price target of $84 — +20.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 4 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores BrightSpring Health Services, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Volatility (36): The share price moves around a lot.
Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BTSG, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +20.3% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Nov 2026 | Guggenheim | Maintains | Buy | $81 → $84 |
| 2 Nov 2026 | Leerink Partners | Maintains | Outperform | $72 → $92 |
| 2 Nov 2026 | TD Cowen | Maintains | Buy | $81 → $84 |
| 2 Nov 2026 | UBS | Maintains | Buy | $85 → $92 |
| 2 Nov 2026 | Wells Fargo | Maintains | Overweight | $78 → $82 |
| 13 Aug 2026 | BTIG | Reiterates | Buy | — |
| 13 Aug 2026 | BTIG | Reiterates | Buy | $90 |
| 3 Aug 2026 | BTIG | Reiterates | Buy | $90 |
| 3 Aug 2026 | BTIG | Reiterates | Buy | — |
| 14 July 2026 | Keybanc | Maintains | Overweight | $60 → $80 |
| 14 July 2026 | Keybanc | Maintains | Overweight | — |
| 14 July 2026 | Morgan Stanley | Maintains | Overweight | $71 → $80 |
| 14 July 2026 | Morgan Stanley | Maintains | Overweight | — |
| 13 July 2026 | Guggenheim | Initiates | Buy | — |
| 13 July 2026 | Guggenheim | Initiates | Buy | $81 |
| 13 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 13 July 2026 | Wells Fargo | Maintains | Overweight | $61 → $78 |
| 10 July 2026 | Raymond James | Initiates | Outperform | $80 |
| 10 July 2026 | Raymond James | Initiates | Outperform | — |
| 8 July 2026 | UBS | Maintains | Buy | $63 → $85 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BTSG appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, BrightSpring Health Services, Inc. returned +117.9% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 15% of US stocks
Cheaper than 70% of US stocks
Cheaper than 13% of US stocks
Cheaper than 12% of US stocks
Higher than 75% of US stocks
Higher than 81% of US stocks
Higher than 12% of US stocks
Higher than 52% of US stocks
Higher than 54% of US stocks
Higher than 75% of US stocks
Higher than 79% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BrightSpring Health Services, Inc. has a market value of $13.9B and an enterprise value of $16.1B.
Revenue in the twelve months to 30 June 2026: $14.4B. The latest quarter grew 26.4% year on year.
Net income over the same four quarters: $365.4M, a 2.5% net margin.
Diluted earnings per share, trailing twelve months: $1.67.
Free cash flow in the twelve months to 30 June 2026: $402.4M.
BrightSpring Health Services, Inc. spent $163.2M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 47.4×; forward P/E: 29.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
BrightSpring Health Services, Inc. employs 23,500 people — $612K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BrightSpring Health Services, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlights BrightSpring’s specialty pharmacy growth, Provider Services expansion, and operational gains, while noting pressures from the IRA and integration risks.
Why it matters — These growth drivers and risks are relevant to BTSG watchers assessing the company’s business momentum and challenges.
Zacks Investment Research explains how its Style Scores help investors find stocks rated highly for a particular investing style, framing BrightSpring Health Services as a long-term value stock.
Why it matters — BTSG watchers may note the article’s value-stock framing and its reference to Zacks’ Style Scores as the basis for that view.
BrightSpring reported an 80% increase in Q3 2026 earnings, with pharmacy and home health growth contributing to a revenue beat and margin expansion. The company also raised its full-year guidance.
Why it matters — The results and higher guidance highlight growth in BrightSpring’s pharmacy and home health businesses.
BrightSpring raised its 2026 guidance after reporting a Q3 earnings beat. Specialty drug launches and home health gains supported its outlook for organic growth in 2027.
Why it matters — The raised guidance and cited business gains provide BTSG watchers with an update on the company’s near-term outlook and expected organic growth.
Seeking Alpha published a transcript of BrightSpring Health Services, Inc.’s Q3 2026 earnings call.
Why it matters — The transcript is a source for BTSG watchers seeking details from the company’s Q3 2026 earnings call.
The 18 Wall Street analysts covering BrightSpring Health Services, Inc. have a median 12-month price target of $84, with estimates ranging from $74 to $92. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering BrightSpring Health Services, Inc., 18 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BrightSpring Health Services, Inc. 93 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, BrightSpring Health Services, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +20.3% from the last close, and Ticker Nerd's factor model ranks BrightSpring Health Services, Inc. 93 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BrightSpring Health Services, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BTSG are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $74 to $92 over the next 12 months.
BrightSpring Health Services, Inc. returned +117.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
BrightSpring Health Services, Inc. is a U.S.
The most recent item we track (Zacks Investment Research, 4 Nov 2026): "Here's Why You Should Retain BTSG Stock in Your Portfolio for Now". Zacks Investment Research highlights BrightSpring’s specialty pharmacy growth, Provider Services expansion, and operational gains, while noting pressures from the IRA and integration risks.
BrightSpring Health Services, Inc. is a U.S. home and community-based healthcare services platform focused on delivering integrated pharmacy and provider solutions for complex patient populations. The company operates through Pharmacy Solutions and Provider Services, offering services such as infusion and specialty pharmacy, home and community pharmacy, home health care, rehabilitation, and other clinical support services. Its care model serves patients across Medicare, Medicaid, and commercial insurance programs, with an emphasis on coordinated, person-centered care in home and community settings. BrightSpring Health Services plays an important role in the healthcare market by connecting pharmacy capabilities with direct care services, supporting patients who require ongoing, specialized, or chronic care management.
CEO Mr. Jon B. Rousseau · 23,500 employees · United States · https://www.brightspringhealth.com
